
Please try another search
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Thomas H. Jensen | 47 | 2004 | Founder, CEO & Director |
Gerald W. McLaughlin | 57 | 2022 | Independent Chairman of the Board |
Daniel Douglas Von Hoff | 77 | - | Member of Scientific Advisory Board |
Ursula A. Matulonis | - | - | Member of Scientific Advisory Board |
Mansoor Raza Mirza | 64 | - | Member of Scientific Advisory Board |
Roberto Pili | - | 2022 | Member of Scientific Advisory Board |
Joyce Ann O'Shaughnessy | - | - | Member of Scientific Advisory Board |
Laura E. Benjamin | 59 | 2023 | Independent Director |
Jesper Høiland | - | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review